68974-400-30 : NDC 2026 Code

68974-400-30 : Sparsentan ( Filspari )

Additionally :

You can get information about “68974-400-30” NDC code in 68974-400-30 in HTML format

HTML | 68974-400-30 in TXT (Plain Text) format

TXT | 68974-400-30 in PDF (Portable Document Format)

PDF | 68974-400-30 in XML format

XML formats.

NDC Code : 68974-400-30 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "68974-400-30",
    "PackageDescription": "30 TABLET, FILM COATED in 1 BOTTLE (68974-400-30) ",
    "NDC11Code": "68974-0400-30",
    "ProductNDC": "68974-400",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Filspari",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Sparsentan",
    "DosageFormName": "TABLET, FILM COATED",
    "RouteName": "ORAL",
    "StartMarketingDate": "20230217",
    "EndMarketingDate": null,
    "MarketingCategoryName": "NDA",
    "ApplicationNumber": "NDA216403",
    "LabelerName": "Travere Therapeutics, Inc.",
    "SubstanceName": "SPARSENTAN",
    "StrengthNumber": "400",
    "StrengthUnit": "mg/1",
    "Pharm_Classes": "Angiotensin 2 Receptor Blocker [EPC], Angiotensin 2 Type 1 Receptor Antagonists [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Endothelin Receptor Antagonist [EPC], Endothelin Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-12-23",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20230217",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}